海思科医药集团股份有限公司关于向特定对象发行股票的审核问询函回复（修订稿）及募集说明书等申请文件更新的提示性公告

Group 1 - The company received an inquiry letter from Shenzhen Stock Exchange regarding its application for a private placement of shares on July 23, 2025 [1] - The company, along with relevant intermediaries, has responded to the inquiry and updated the application documents, including financial data, to reflect the first half of 2025 [2] - The issuance of shares is subject to approval from Shenzhen Stock Exchange and registration consent from China Securities Regulatory Commission, with uncertainties regarding the approval timeline [2] Group 2 - The company will fulfill its information disclosure obligations in accordance with regulations as the matter progresses [2] - The board of directors announced the updates on September 6, 2025 [3]